Current approaches to the diagnostics and treatment of acromegaly
- Autores: Antsiferov M.B.1, Alekseeva T.M1, Andreeva A.V2
-
Afiliações:
- Endocrinological Dispensary of the Moscow Healthcare Department
- V.V. Veresaev City Clinical Hospital, Moscow Healthcare Department
- Edição: Volume 26, Nº 4 (2019)
- Páginas: 100-104
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/297981
- DOI: https://doi.org/10.18565/pharmateca.2019.4.100-104
- ID: 297981
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Acromegaly is a severe chronic neuroendocrine disease that requires timely, adequate diagnosis and therapy. In the diagnosis of acromegaly, determination of the insulin-like growth factor-1 and growth hormone levels, as well as neuroimaging, play a key role. In the treatment of acromegaly, surgery is the best choice. In the absence of ability of surgical intervention or in the case of non-radicality of the surgical treatment, the pharmacotherapy is indicated. Somatostatin analogues (SSA) today are the most effective means of drug control of secretory and proliferative tumor activity. In the case of resistance to SSA, it is possible to transfer to another SSA, increase the dose of SSA, or add dopamine agonists and growth hormone receptor antagonists to the SSA.
Palavras-chave
Texto integral
Sobre autores
Mikhail Antsiferov
Endocrinological Dispensary of the Moscow Healthcare Department
Email: antsiferov@rambler.ru
MD, Professor, Chief Moscow, Russia
T. Alekseeva
Endocrinological Dispensary of the Moscow Healthcare DepartmentMoscow, Russia
A. Andreeva
V.V. Veresaev City Clinical Hospital, Moscow Healthcare DepartmentMoscow, Russia
Bibliografia
- Анциферов М.Б., Астафьева Л.И. Акромегалия и коморбидность: диагностика и лечение. Фарматека. 2018;4:23-6.
- Дедов И.И., Мельниченко Г.А. и др. Акромегалия: клиника, диагностика, дифференциальная диагностика, методы лечения. Клинические рекомендации. Российская ассоциация эндокринологов. М., 2014.
- Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006;355(24):2558-73.
- Holdaway I.M., Bolland M.J., Gamble G.D., et al. A meta-analysis of the effect of lowering serum levels of GH and !GF-! on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.
- Анциферов М.Б., Пронин В.С. Опыт ведения московского регистра больных акромегалией: возможности решения различных терапевтических задач. Фарматека. 2013;16:40-5.
- Caron P., Bevan J., Clermont A., Maisonobe P. Early and sustained tumour volume reduction and GH/!GF1 control in patients with GH-secreting pituitary acroadenoma primarily treated with lanreotide Autogel 120 mg for 48 weeks: the Primarys study. The 15th European congress of Endocrinology, 2013.
- Caron P., Cogne M., Raingeard !., et al. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol. (Oxf.). 2006;64(2): 209-14.
- Florio T., Thellung S., Corsaro A., et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol. (Oxf.). 2003; 59:115-28.
- Katznelson L., Atkinson J.L., Cook D.M., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 update: executive summary. Endocr Pract. 2011;17(4):636-46.
- Melmed S., Colao A., Barkan A., et al. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-17.
- Анциферов М.Б., Алексеева Т.М. Московский регистр больных акромегалией: отдаленные результаты наблюдения. Фарматека. 2016;16:62-6.
- Neggers S., Pronin V., Balcere I. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol. 2015;173:313-23.
- Caron P.J. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the Primarys study. Clin Endocrinol. 2016. Doi: 10.1111/ cen.13285.
- Abreu A., Tovar A.P., Castellanos R., et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19:448-57. doi: 10.1007/s11102-016-0725-2.
- Annamalai A.K., Webb A., Kandasamy N., et al. A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy. J Clin Endocrinol Metab. 2013;98(3):1040-50.
Arquivos suplementares
